Trevena announces TRV 027 selected for study in global REMAP-CAP trial in COVID-19 patients.

Trevena, Inc. announced that TRV 027, the Company’s novel AT1 receptor selective agonist, has been selected for inclusion in an international, multi-site, adaptive, Phase II-Phase III trial in COVID-19 patients . The trial is being conducted and funded as part of REMAP-CAP (Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia), a global network of clinicians, institutions, and research facilities with the objective of evaluating treatments with the potential to reduce mortality, ICU use, and morbidity in severely ill patients with COVID-19. REMAP-CAP is financially supported by an array of governments and research organizations worldwide. The trial, known as the REMAP-CAP COVID-19 ACE2 RAS Modulation Domain, is designed specifically to evaluate treatments targeting the renin-angiotensin system (RAS) and determine whether modulation of the RAS is an effective strategy for preventing multiorgan failure and mortality in hospitalized COVID-19 patients. TRV 027, which is based on Nobel Prize winning technology, combats disruption within the RAS by specifically binding to and rebalancing AT1 receptor activation, blocking the damaging pathway that leads to acute lung damage and abnormal blood clotting, while activating the cellular pathway that selectively targets reparative actions that improve lung function and promote anti-inflammatory effects. About the REMAP-CAP COVID-19 ACE2 RAS Modulation Domain : This is an international, multi-site, randomised, Phase II-Phase III adaptive clinical trial in hospitalized patients with acute illness due to suspected or proven COVID-19, including patients admitted to ICU. Four active treatments are included in the study protocol, including TRV 027, with 200-300 patients expected to be enrolled in each arm. TRV 027 will be administered in conjunction with an ACE inhibitor. The primary outcome is a composite of in-hospital mortality and provision of organ failure support while admitted to an ICU in the 21 days following randomization. The trial is also evaluating clinical outcomes including ICU and hospital length of stay, ventilator-free days, and organ failure-free days.